➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
Baxter
McKesson
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 7,084,118

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,084,118
Title:Combination treatment with t-PA variant and low molecular weight heparin
Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Inventor(s): Armstrong; Paul (Edmonton, CA), Barron; Hal (San Francisco, CA), Berioli; Silvano (Perugia, IT), Bigonzi; Frederique (1\'Hay les Roses, FR), Bluhmki; Erich (Schwendi, DE), Chin; Richard (San Francisco, CA), Granger; Christopher (Durham, NC), Van De Werf; Frans (Herent, BE), Wang-Clow; Fong (Los Altos Hills, CA)
Assignee: Genentech, Inc. (South San Francisco, CA) Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT) Aventis Pharma, S.A. (Antony, FR) Boehringer Ingelheim Pharma KG (Ingelheim/Rhein, DE)
Application Number:10/371,778
Patent Claims:see list of patent claims

Details for Patent 7,084,118

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech TNKASE tenecteplase VIAL 103909 001 2000-06-02   Start Trial Genentech, Inc. (South San Francisco, CA) Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT) Aventis Pharma, S.A. (Antony, FR) Boehringer Ingelheim Pharma KG (Ingelheim/Rhein, DE) 2022-02-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
AstraZeneca
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.